Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa


EC approval decision anticipated in second quarter of 2025 EC approval decision anticipated in second quarter of 2025

Read the rest here:
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Related Posts